Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Cost of Revenue (2022 - 2025)

Axsome Therapeutics' Cost of Revenue history spans 4 years, with the latest figure at $12.3 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 17.26% year-over-year to $12.3 million; the TTM value through Dec 2025 reached $47.5 million, up 42.56%, while the annual FY2025 figure was $47.5 million, 42.56% up from the prior year.
  • Cost of Revenue for Q4 2025 was $12.3 million at Axsome Therapeutics, up from $11.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $13.4 million in Q2 2025 and bottomed at $983000.0 in Q2 2022.
  • The 4-year median for Cost of Revenue is $7.6 million (2023), against an average of $7.5 million.
  • The largest annual shift saw Cost of Revenue skyrocketed 367.85% in 2023 before it fell 16.66% in 2024.
  • A 4-year view of Cost of Revenue shows it stood at $2.3 million in 2022, then soared by 222.0% to $7.4 million in 2023, then surged by 42.5% to $10.5 million in 2024, then grew by 17.26% to $12.3 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Cost of Revenue are $12.3 million (Q4 2025), $11.9 million (Q3 2025), and $13.4 million (Q2 2025).